Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
复制标题
DOI：
10.1517/14712598.2012.642359
复制
发表时间：
2012-01
影响因子：
4.6
通讯作者：
Calhoun WJ
中科院分区：
文献类型：
--
作者：
Ghazi A;Trikha A;Calhoun WJ
Benralizumab是一种将受体α亚基与IL-5结合的单克隆抗体。由于IL-5与嗜酸性粒细胞介导的疾病状态有关，benralizumab在哮喘治疗中是一个有吸引力的选择。由于增强的抗体定向细胞毒性，与针对IL-5的中和单克隆抗体相比，它具有增强的嗜酸性粒细胞消耗活性。本综述介绍了benralizumab的现有数据，包括药效学、药代动力学、临床前数据和相关临床研究。我们的综述表明，尽管需要进一步的研究来证明临床益处，但贝纳利珠单抗仍然是一种有希望的治疗方式。
Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.
登录
查看更多内容
影响因子：
20.3
作者：
Ogata, N;Kouro, T;Takatsu, K
通讯作者：
Takatsu, K
影响因子：
14.2
作者：
Stein, Miguel L.;Villanueva, Joyce M.;Rothenberg, Marc E.
通讯作者：
Rothenberg, Marc E.
影响因子：
14.2
作者：
Busse, William W.;Katial, Rohit;Molfino, Nestor A.
通讯作者：
Molfino, Nestor A.
影响因子：
5.3
作者：
TAKAKI, S;KANAZAWA, H;TAKATSU, K
通讯作者：
TAKATSU, K
影响因子：
--
作者：
Koike, Masamichi;Nakamura, Kazuyasu;Hanai, Nobuo
通讯作者：
Hanai, Nobuo